Rozlytrek (entrectinib) / Nerviano Medical Sciences, Roche  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rozlytrek (entrectinib) / Roche
2019-003859-11: A Study of Entrectinib versus Crizotinib in Patients with Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases

Ongoing
3
220
Europe, RoW
Entrectinib, Crizotinib, RO7102122 - F04/F06/F10/F14/F24, RO7102122 - F08/F09/F11/F20/F25, Capsule, hard, XALKORI
F.Hoffmann-La Roche Ltd, Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements, Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung, Diseases [C] - Cancer [C04]
 
 
NCT04603807 / 2019-003859-11: A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Recruiting
3
220
Europe, RoW
Entrectinib, Crizotinib
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
12/27
12/27
NCT05170204 / 2021-004149-19: A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
121
Europe, Canada, Japan, US, RoW
Alectinib, Entrectinib, Durvalumab
Hoffmann-La Roche
Non-Small Cell Lung Cancer
06/29
04/35
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, GDC-6036, RO7435846, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
DETERMINE, NCT05722886: (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29

Download Options